Table 1.

Clinical Characteristics of Study Participants

Cases (n)	4073
Ethnicity	Caucasian
Age at diagnosis (n)	3983
Mean (yrs)	61.3
Median (Q1, Q3)	61 (55, 67)
Biopsy Gleason Score at diagnosis (n)	3750
<7 (%)	1771 (47.2)
7 (%)	1272 (33.9)
>7 (%)	707 (18.9)
Clinical stage (n)*	3056
T1–T2 (%)	2807 (91.9)
T3–T4 (%)	65 (2.1)
N1 (%)	46 (1.5)
M1 (%)	138 (4.5)
PSA at diagnosis (n)	3518
Median (ng/mL)(Q1, Q3)	6 (5,11)
D’ Amico risk classification (%)	3347
Low	1004 (30.0)
Intermediate	1357 (40.5)
High	986 (29.5)
RP sub-cohort (n)	1716
RP Gleason Score (n)	1692
<7 (%)	652 (38.5)
7 (%)	769 (45.5)
>7 (%)	271 (16.0)
Pathologic stage (n)*	1716
T1–T2 (%)	1161 (67.7)
T3–T4 (%)	475 (27.7)
N1 (%)	76 (4.4)
M1 (%)	4 (0.2)

^*:T1–T2 represented for T1–T2, N0 or Nx, M0 or Mx; T3–T4 represent for T3–T4, N0 or Nx, M0 or Mx; N1 represent for T1–T4 or Tx, N1, M0 or Mx; M1 represent for T1–T4 or Tx, N0 or Nx, M1 according to AJCC staging.